Company

Bank

Analyst

Coverage

Opinion

Wk chg

7/12 cls

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN)

Maxim Group

Jason Kolbert

Downgrade

Hold (from buy)

12%

$6.95

Kolbert also removed his $18 target after FDA placed a partial clinical hold on sovaprevir. The decision followed data from a Phase I drug-drug interaction study that showed sovaprevir plus ritonavir-boosted atazanavir led to elevations of alanine aminotransferase (ALT) in healthy volunteers (see B44). Kolbert said that "coming back from clinical holds historically has been difficult for HCV therapies." Sovaprevir is a selective inhibitor of HCV NS3 protease. Achillion was down 24% for the week ended July 5, when Kolbert issued his report.

Onyx Pharmaceuticals Inc. (NASDAQ:ONXX)

Baird

Christopher Raymond

Price target

Outperform

-2%

$133.00

Barclays Capital

Ying Huang

Price target

Overweight

Bernstein Research

Geoffrey Porges

Price target

Market perform

BMO Capital Markets

Jim Birchenough

Price target

Outperform

Brean Capital

Gene Mack

Price target

Buy

Deutsche Bank

Robyn Karnauskas

Price target

Buy

JPMorgan

Cory Kasimov

Price target

Overweight

Leerink

Howard Liang

Price target

Outperform